Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer

Kristian Hastoft Jensen*, Gitte Persson, Anna Louise Bondgaard, Mette Pøhl

*Corresponding author for this work

Research output: Contribution to journalLetterResearchpeer-review

34 Citations (Scopus)
3 Downloads (Pure)

Abstract

Pharmaceutical blockade of immune checkpoint inhibitors has become a cornerstone in the treatment of several malignancies. Many patients experience immune-related adverse events [Citation1]. However, treatment-related development or reactivation of infectious disease is rarely reported. Here, we present a patient with advanced non-small cell lung cancer (NSCLC), who developed tuberculosis (TB) following treatment with nivolumab, an anti-PD-1 monoclonal antibody.
Original languageEnglish
JournalActa Oncologica
Volume57
Issue number8
Pages (from-to)1127-1128
Number of pages2
ISSN0284-186X
DOIs
Publication statusPublished - 3 Aug 2018

Cite this